You are here

Merck

FDA gives Merck priority review for blood vessel disorder therapy sotatercept

FDA gives Merck priority review for blood vessel disorder therapy sotatercept

Medical Marketing and Media

Flag link:

Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo

Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo

BioSpace

urothelial cancer

clinical trials

Flag link:

Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer

Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer

Fierce Pharma

colorectal cancer

non-small cell lung cancer

Flag link:

Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag

Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag

Yahoo/Zacks.com

cervical cancer

priority review

Flag link:

1ST Biotherapeutics and Merck to assess cancer combination treatment

1ST Biotherapeutics and Merck to assess cancer combination treatment

Clinical Trials Arena

1st Biotherapeutics

clinical trials

Flag link:

HHS argues Merck 'lacks standing' to sue over Medicare price negotiations

HHS argues Merck 'lacks standing' to sue over Medicare price negotiations

Fierce Pharma

Inflation Reduction Act

Flag link:

Merck keeps pumping up sotatercept, posting fresh data ahead of FDA approval ruling

Merck keeps pumping up sotatercept, posting fresh data ahead of FDA approval ruling

Fierce Biotech

cardiovascular disease

Flag link:

Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts

Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts

Fierce Pharma

Flag link:

5 of the best places to work in pharma, according to employees

5 of the best places to work in pharma, according to employees

Pharma Voice

Flag link:

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

Drugs.com

clinical trials

hypercholesterolemia

Flag link:

Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer

Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer

BioSpace

clinical trials

head and neck cancer

Flag link:

Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program

Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program

Fierce Biotech

PCSK9 inhibitors

clinical trials

cardiovascular disease

Flag link:

Merck’s Keytruda to top drug sales in 2028, as Roche takes pharma crown

Merck’s Keytruda to top drug sales in 2028, as Roche takes pharma crown

Medical Marketing and Media

Flag link:

Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown

Merck's Keytruda will top pharma's sales rankings in 2028, with Roche taking the company category crown

Fierce Pharma

Flag link:

Merck’s Welireg Clears Phase III Primary Endpoint in Renal Cell Carcinoma

Merck’s Welireg Clears Phase III Primary Endpoint in Renal Cell Carcinoma

BioSpace

renal cell carcinoma

clinical trials

Flag link:

Gilead antibody drug shows signs of potential in early lung cancer

Gilead antibody drug shows signs of potential in early lung cancer

BioPharma Dive

Gilead Sciences

Flag link:

The 10 drugs that CMS might wrangle into negotiations

The 10 drugs that CMS might wrangle into negotiations

Beckers Hospital Review

Bristol Myers Squibb

Boehringer Ingelheim

Flag link:

Merck and Astex announce expansion to oncology drug discovery collaboration

Merck and Astex announce expansion to oncology drug discovery collaboration

Pharma Live

small molecule drugs

Flag link:

Pages